{"disease":{"id":"advanced-cancers-associated-with-mesothelin-expression","name":"advanced cancers associated with mesothelin expression"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03872206","title":"Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}